信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

III 信息服务

劳工日休市 08-29 16:00:00 EDT

5.17

+0.05

+0.98%

盘后5.17

+0.000.00%

16:20 EDT

最高5.19	最低5.08	成交量16.17万
今开5.12	昨收5.12	日振幅2.15%
总市值2.49亿	流通市值1.77亿	总股本4,820万
成交额83.30万	换手率0.47%	流通股本3,423万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"III","market":"US","secType":"STK","nameCN":"信息服务","latestPrice":5.17,"timestamp":1756497600000,"preClose":5.12,"halted":0,"volume":161715,"hourTrading":{"tag":"盘后","latestPrice":5.17,"preClose":5.17,"latestTime":"16:20 EDT","volume":2675,"amount":13829.75,"timestamp":1756498823284},"delay":0,"floatShares":34233044,"shares":48195469,"eps":0.156933,"marketStatus":"劳工日休市","change":0.05,"latestTime":"08-29 16:00:00 EDT","open":5.12,"high":5.19,"low":5.08,"amount":832977.227498,"amplitude":0.021484,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.156933,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1171256400000,"exchange":"NASDAQ","adjPreClose":5.12,"dividendRate":0.034816,"preHourTrading":{"tag":"盘前","latestPrice":5.0601,"preClose":5.12,"latestTime":"08:22 EDT","volume":1246,"amount":6394.5147378,"timestamp":1756470128017},"postHourTrading":{"tag":"盘后","latestPrice":5.17,"preClose":5.17,"latestTime":"16:20 EDT","volume":2675,"amount":13829.75,"timestamp":1756498823284},"volumeRatio":0.9341316321116475,"impliedVol":0.54,"impliedVolPercentile":0.296},"requestUrl":"/m/hq/s/III","defaultTab":"news","newsList":[{"id":"2564898466","title":"礼来Muvalaplin片启动III期临床 适应症为降低伴Lp(a)水平升高患者MACE发生风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2564898466","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564898466?lang=zh_cn&edition=full","pubTime":"2025-09-01 12:31","pubTimestamp":1756701060,"startTime":"0","endTime":"0","summary":"本次试验主要目的为在伴有Lp水平升高且发生过ASCVD事件或发生首次ASCVD事件风险升高的成人参与者中评价Muvalaplin对主要不良心血管事件影响。Muvalaplin片为化学药物，适应症为在伴Lp水平升高且已确诊CVD或发生首次CVE风险升高的患者中，降低MACE的发生风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250901123802976f95b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1366192091.USD","LU0238689110.USD","SG9999018857.SGD","LU0672654240.SGD","LU0471298777.SGD","LLY","LU2602419157.SGD","MACE","LU2471134952.CNY","LU0256863902.USD","LU1061106388.HKD","SG9999018865.SGD","LU2468319806.SGD","BK4588","BK4599","LU0385154629.USD","LU0203201768.USD","LU2746668974.SGD","LU0432979614.USD","SGXZ99366536.SGD","LU2746668461.USD","SGXZ51526630.SGD","LU1280957306.USD","IE00B2B36J28.USD","LU1548497426.USD","LU0823434583.USD","LU0122379950.USD","GB00BDT5M118.USD","LU2491050071.SGD","LU2552382215.SGD","Y","LU2237443549.SGD","LU0079474960.USD","LU1267930730.SGD","LU0889565916.HKD","SGXZ57979304.SGD","LU0109391861.USD","LU0198837287.USD","LU0094547139.USD","LU1720051017.SGD","SGXZ81514606.USD","LU2461242641.AUD","LU1974910355.USD","LU0114720955.EUR","LU0354030511.USD","LU0097036916.USD","LU2237443622.USD","III","LU2237438978.USD","LU2750360997.AUD","LU0466842654.USD"],"gpt_icon":1},{"id":"2563886260","title":"阿斯利康：巴昔多司他（Baxdrostat）在BaxHTN III期试验中达到主要终点和所有次要终点。 巴昔 多司他2毫","url":"https://stock-news.laohu8.com/highlight/detail?id=2563886260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563886260?lang=zh_cn&edition=full","pubTime":"2025-08-30 22:16","pubTimestamp":1756563415,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4007","LU0320765992.SGD","AZN","LU0109394709.USD","LU2236285917.USD","III","LU2417539215.USD","LU1829250122.USD","LU2456880835.USD","BK4568","BK4134","LU2462157665.USD","LU0889565916.HKD","BK4588","BK4585"],"gpt_icon":0},{"id":"2563888629","title":"阿斯利康：在BAXHTN III期试验中巴昔多司他（baxdrostat）使患者的收缩压出现了具有临床意义的降低。 阿斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2563888629","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563888629?lang=zh_cn&edition=full","pubTime":"2025-08-30 22:15","pubTimestamp":1756563336,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","LU2417539215.USD","LU0889565916.HKD","AZN","BK4588","LU2236285917.USD","BK4134","LU0109394709.USD","LU2456880835.USD","BK4007","LU2462157665.USD","III","BK4568","LU1829250122.USD","BK4585"],"gpt_icon":0},{"id":"2563204139","title":"万邦德：石杉碱甲控释片II/III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2563204139","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563204139?lang=zh_cn&edition=full","pubTime":"2025-08-29 18:24","pubTimestamp":1756463066,"startTime":"0","endTime":"0","summary":"万邦德(002082.SZ)公告称，公司全资子公司万邦德制药集团有限公司的2.2类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病型痴呆的II/III期关键注册临床试验，近日完成首例受试者入组。该研究是中国目前已知规模最大的阿尔茨海默病注册研究，采用多中心、随机、双盲双模拟的设计，并设有安慰剂和阳性药双对照。石杉碱甲控释片是公司自主研发的2.2类新药，采用双相控释技术，旨在实现快速起效，减少不良反应，并提高患者的用药便利性和长期依从性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/29182452811524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0004","BK0028","BK0050","BK4134","002082","BK0239","III"],"gpt_icon":0},{"id":"2563010770","title":"国家外汇管理局公布2025年7月我国国际收支货物和服务贸易数据数据显示2025年7月我国国际收支货物和服务贸易进出口规模","url":"https://stock-news.laohu8.com/highlight/detail?id=2563010770","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563010770?lang=zh_cn&edition=full","pubTime":"2025-08-29 17:03","pubTimestamp":1756458224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["III","BK4134","159998"],"gpt_icon":0},{"id":"2562031124","title":"全球首个PD-L1 ADC启动III期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2562031124","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562031124?lang=zh_cn&edition=full","pubTime":"2025-08-28 15:27","pubTimestamp":1756366034,"startTime":"0","endTime":"0","summary":"8月27日，全球临床试验收录网站显示，辉瑞启动了PD-L1 ADC药物PF-08046054的首个III期临床试验。该药物是首个进入III期阶段的PD-L1 ADC。截至2024年12月20日，共30例经治NSCLC患者入组接受1.5mg/kg PF-08046054治疗。结果显示，研究者评估的确认客观缓解率为26.7%，其中肿瘤表达PD-L1患者的cORR为32.0%。目前，全球共有5款在研PD-L1 ADC，包括PF-08046054、HLX43、AT-001、IMD2126以及Lanier Biotherapeutics公司的一款未有研发代号的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828154028a4a473c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250828154028a4a473c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4231","III","BK4201","LU1169590202.USD","ADC","BK4080","E","BK4134","BK4023","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"2562170031","title":"辉瑞Sigvotatug Vedotin启动III期临床 适应症为PD-L1高表达的非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2562170031","media":"新浪财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562170031?lang=zh_cn&edition=full","pubTime":"2025-08-28 12:03","pubTimestamp":1756353780,"startTime":"0","endTime":"0","summary":"本次试验主要目的为证明Sigvotatug Vedotin + 帕博利珠单抗在延长OS和BICR评估的PFS方面优于帕博利珠单抗单药；次要目的包括比较两组间BICR评估的客观缓解率，评价其他有效性指标，评估安全性和耐受性特征，以及评估联合给药时的药代动力学和免疫原性。Sigvotatug Vedotin为生物制品，适应症为PD-L1高表达的非小细胞肺癌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082812485395021e2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082812485395021e2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BBT3K403.USD","LU1169589451.USD","SG9999013999.USD","BK4533","LU0122379950.USD","LU0170899867.USD","LU0306806265.USD","SG9999003800.SGD","BK4599","BK4568","LU0321505439.SGD","LU1894683264.USD","PFE","LU1883839398.USD","IE00B19Z3B42.SGD","BK4201","LU0234572021.USD","LU0225771236.USD","BK4134","SGXZ57979304.SGD","LU0225284248.USD","LU0306807586.USD","IE00BLSP4452.SGD","BK4007","LU0985481810.HKD","E","LU1169590202.USD","LU1066051498.USD","LU1066053197.SGD","BK4534","LU1894683348.USD","IE000M9KFDE8.USD","BK4023","III","IE00B19Z3581.USD","LU0456855351.SGD","BK4550","IE0002270589.USD","IE00BLSP4239.USD","SG9999001176.USD","BK4581","LU0321505868.SGD","BK4588","PD","SG9999002232.USD","LU1057294990.SGD","LU0058720904.USD","BK4592","LU0868494617.USD"],"gpt_icon":1},{"id":"2562775669","title":"珠海润都制药股份有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2562775669","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562775669?lang=zh_cn&edition=full","pubTime":"2025-08-28 06:03","pubTimestamp":1756332238,"startTime":"0","endTime":"0","summary":"金融界8月28日消息，据CDE官网沟通交流公示，于8月28日收到珠海润都制药股份有限公司申请的“III类会议”，当前状态“处理中”。珠海润都制药股份有限公司，成立于1999年，位于珠海市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，珠海润都制药股份有限公司共对外投资了6家企业，参与招投标项目4669次，知识产权方面有商标信息372条，专利信息390条，此外企业还拥有行政许可423个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/28060352759398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01477","BK1191","BK4134","BK1574","III"],"gpt_icon":0},{"id":"2562742914","title":"四款重磅大单品即将上市，创新驱动艾美疫苗估值向上","url":"https://stock-news.laohu8.com/highlight/detail?id=2562742914","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562742914?lang=zh_cn&edition=full","pubTime":"2025-08-27 21:57","pubTimestamp":1756303023,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["SG9999013478.USD","RJAW.SI","LU0557290698.USD","LU0205439572.USD","SG9999002620.SGD","LU0955623706.USD","LU0971096721.USD","SG9999011175.SGD","D05.SI","LU0898667661.SGD","SG9999002414.USD","SGXZ24219693.SGD","LU0831103253.SGD","III","LU0878005551.USD","LU1839390173.USD","SGXZ58947870.SGD","LU2506952170.USD","LU0577902298.EUR","LU0345775950.USD","LU0532188223.SGD","LU0672654166.SGD","LU0251143029.SGD","LU0210637038.USD","BK4134","SG9999002406.SGD","IE00BVYPNQ40.USD","DBS","LU0543330483.HKD","LU0188438112.USD","LU0823413587.USD","SG9999014484.SGD","LU1504937902.USD","LU2506951958.HKD","LU0384037296.USD","LU0048597586.USD","LU0441854154.USD","SG9999013486.USD","LU0823417653.USD","SG9999016042.SGD","LU0878004406.USD","06660","LU1363072403.SGD","LU1956131251.USD","SG9999003800.SGD","159646","SG9999014302.SGD","LU0261947096.USD","LU0192582467.USD","LU1282649067.USD"],"gpt_icon":0},{"id":"2562176147","title":"荣昌生物(09995)：泰它西普(商品名：泰爱®)治疗IgA肾病中国III期临床研究A阶段达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2562176147","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562176147?lang=zh_cn&edition=full","pubTime":"2025-08-27 18:33","pubTimestamp":1756290829,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，公司自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普用于治疗IgA肾病的中国III 期临床研究，达到A阶段的主要研究终点。IgA肾病也是中国慢性肾脏病和终末期肾病的主要原因之一，高达40%的 IgA肾病患者在诊断后20年内达到终末期肾病，产生对新型药物迫切的未满足医疗需求。目前学术界认为，半乳糖缺乏型IgA1分泌过多是IgA肾病的发病的核心及始动因素。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1336343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","LU1064131003.USD","BK0239","LU1064130708.USD","688331","LU1969619763.USD","BK1574","BK4134","LU2328871848.SGD","09995","III","BK1583","LU2148510915.USD","BK1161"],"gpt_icon":0},{"id":"2562891754","title":"美国国防部：美国国务院批准向英国出售C - 17“环球霸王III”运输机维护支持服务，预估成本8.61亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562891754","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562891754?lang=zh_cn&edition=full","pubTime":"2025-08-27 03:19","pubTimestamp":1756235955,"startTime":"0","endTime":"0","summary":"美国国防部：美国国务院批准向英国出售C - 17“环球霸王III”运输机维护支持服务，预估成本8.61亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/08/27031952719771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2562737325","title":"埃克森美孚：将日产约8000桶III类基础油。","url":"https://stock-news.laohu8.com/highlight/detail?id=2562737325","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562737325?lang=zh_cn&edition=full","pubTime":"2025-08-26 22:27","pubTimestamp":1756218444,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0300736062.USD","LU0203347892.USD","LU1267930813.SGD","XOM","LU0788109394.HKD","LU0266512473.USD","LU1732800096.USD","LU1883866441.USD","SG9999001440.SGD","BK4201","LU0985489474.SGD","SG9999002224.SGD","LU0912757837.SGD","LU2430703178.SGD","IE00BWXC8680.SGD","SG9999002521.SGD","IE00BGHQF524.EUR","LU2498475776.HKD","LU2430703251.USD","BK4585","LU0320765646.SGD","LU0278409577.USD","LU0612318971.USD","SG9999014559.SGD","III","LU1732799900.SGD","LU0878866978.SGD","LU0792757196.USD","BK4588","LU0456854461.SGD","LU1066051498.USD","LU0122376428.USD","LU1066053197.SGD","LU0300736492.USD","LU2462611646.USD","LU1582987597.SGD","IE00B2Q91V27.USD","LU0889566641.SGD","SG9999014575.USD","LU2133065610.SGD","BK4592","IE00BKDWB100.SGD","LU1430597077.USD","LU1929549753.HKD","LU0795875169.SGD","LU2592432038.USD","IE0034235303.USD","LU0612318385.USD","BK4134","SG9999015358.SGD"],"gpt_icon":0},{"id":"2562851736","title":"礼来公布口服GLP-1RA III期临床结果，肥胖适应症预计今年在美提交","url":"https://stock-news.laohu8.com/highlight/detail?id=2562851736","media":"时代财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562851736?lang=zh_cn&edition=full","pubTime":"2025-08-26 20:06","pubTimestamp":1756209973,"startTime":"0","endTime":"0","summary":"本文来源：时代财经8月26日晚间，时代财经获悉，礼来制药公布了每日一次口服小分子GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。据悉，礼来计划于2025年向美国食品药品管理局提交 orforglipron用于肥胖症治疗的上市许可申请，并于2026年初针对糖尿病治疗启动申报流程。此外，礼来全球高级副总裁、礼来中国药物开发及医学事务中心负责人王莉博士表示，中国已同步加入了orforglipron的全球研发，期待 orforglipron 能早日在中国获批，为中国患者带来新的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025082620085194fde36f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SGXZ57979304.SGD","SG9999015952.SGD","BK4144","LU1366192091.USD","LU0203202063.USD","LU1623119135.USD","SGXZ99366536.SGD","LU0882574139.USD","LU2360106947.USD","LU0122379950.USD","LU0256863902.USD","SG9999014906.USD","SG9999018857.SGD","LU0354030438.USD","LU2211815571.USD","LU2461242641.AUD","LU0640476718.USD","LU2237443622.USD","LU0320765992.SGD","LU0820561818.USD","LU1061106388.HKD","LU1069344957.HKD","LU1868837136.USD","LU2471134952.CNY","LU0114720955.EUR","BK4599","LU0672654240.SGD","LU2417539215.USD","SG9999018865.SGD","SGXZ51526630.SGD","LU0058720904.USD","LU2237443895.HKD","LU2746668974.SGD","LU0323591593.USD","LLY","SG9999015945.SGD","III","LU0471298694.HKD","LU0094547139.USD","LU0820561909.HKD","LU2023250504.SGD","LU1232071149.USD","LU1974910355.USD","LU0266013472.USD","IE00BK4W5M84.HKD","GLP","SG9999001176.USD","SGXZ81514606.USD","LU0471298777.SGD","SG9999014880.SGD"],"gpt_icon":1},{"id":"2562781007","title":"连续9天少于50例，佛山终止突发公共卫生事件III级响应","url":"https://stock-news.laohu8.com/highlight/detail?id=2562781007","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562781007?lang=zh_cn&edition=full","pubTime":"2025-08-26 17:23","pubTimestamp":1756200180,"startTime":"0","endTime":"0","summary":"南方财经记者高慧超 实习生魏圆昊 佛山报道8月26日，佛山市召开基孔肯雅热疫情防控新闻发布会，决定终止佛山市突发公共卫生事件III级响应，疫情防控策略由应急处置转为常态化防控，统筹推进疫情防控与经济社会发展。截至8月25日，佛山每日新增报告病例连续9天维持在50例以下，全市疫情进入低水平散发状态。下阶段，佛山将从两个方面着力，科学精准高效开展疫情防控工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-08-26/doc-infnhzqa1561053.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-08-26/doc-infnhzqa1561053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4134","III"],"gpt_icon":0},{"id":"2562697273","title":"瑞石生物医药有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2562697273","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562697273?lang=zh_cn&edition=full","pubTime":"2025-08-26 05:35","pubTimestamp":1756157704,"startTime":"0","endTime":"0","summary":"金融界8月26日消息，据CDE官网沟通交流公示，于8月26日收到瑞石生物医药有限公司申请的“III类会议”，当前状态“处理中”。瑞石生物医药有限公司，成立于2018年，位于上海市，是一家以从事研究和试验发展为主的企业。通过天眼查大数据分析，瑞石生物医药有限公司知识产权方面有商标信息12条，专利信息37条，此外企业还拥有行政许可8个。主要股东信息显示，瑞石生物医药有限公司由Reistone Biopharma  Limited持股100%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26053552680458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["161726","399441","BK4134","III"],"gpt_icon":0},{"id":"2562829322","title":"信达生物：IBI363获美国FDA批准开展治疗鳞状非小细胞肺癌III期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2562829322","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562829322?lang=zh_cn&edition=full","pubTime":"2025-08-25 08:49","pubTimestamp":1756082940,"startTime":"0","endTime":"0","summary":"南方财经8月25日电，信达生物宣布其自主研发的PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363的首个全球III期临床研究（MarsLight-11）的新药临床试验申请（IND）获美国食品药品监督管理局（FDA）批准，用于治疗免疫耐药的鳞状非小细胞肺癌（NSCLC）患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202508253492923460.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01801","BK1583","III","BK1589","LU1969619763.USD","LU2488822045.USD","BK4134","BK1161","LU2328871848.SGD"],"gpt_icon":0},{"id":"2561285539","title":"江苏中新医药有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2561285539","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561285539?lang=zh_cn&edition=full","pubTime":"2025-08-23 05:26","pubTimestamp":1755897971,"startTime":"0","endTime":"0","summary":"江苏中新医药有限公司，成立于2011年，位于南京市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，江苏中新医药有限公司共对外投资了1家企业，参与招投标项目1次，知识产权方面有商标信息8条，专利信息13条，此外企业还拥有行政许可40个。主要股东信息显示，江苏中新医药有限公司由江苏康缘药业股份有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/23052652636875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1515","09939","159938","BK1574","III","BK4134","BK1161"],"gpt_icon":0},{"id":"2561479232","title":"同花顺公告2025年上半年营业收入17.79亿元同比增长28.07%。净利润5.02亿元同比增长38.29%。报告期内公","url":"https://stock-news.laohu8.com/highlight/detail?id=2561479232","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561479232?lang=zh_cn&edition=full","pubTime":"2025-08-22 19:55","pubTimestamp":1755863747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK0095","BK0188","BK4134","BK0187","SG9999002950.SGD","SG9999001093.SGD","300033","161631","SG9999001051.SGD","BK0272","BK0012","BK0196","III","SG9999001069.SGD","BK0028"],"gpt_icon":0},{"id":"2561423761","title":"杭州九源基因生物医药股份有限公司申请III类会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2561423761","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561423761?lang=zh_cn&edition=full","pubTime":"2025-08-22 14:26","pubTimestamp":1755843969,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司，成立于1993年，位于杭州市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，杭州九源基因生物医药股份有限公司共对外投资了1家企业，参与招投标项目1106次，知识产权方面有商标信息38条，专利信息53条，此外企业还拥有行政许可74个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/22142652612264.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","III","161726","BK4134","399441","02566"],"gpt_icon":0},{"id":"2561444376","title":"港股异动 | 康方生物(09926)涨超5%创新高 AK111治疗强直性脊柱炎III期临床研究达到全部疗效终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2561444376","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561444376?lang=zh_cn&edition=full","pubTime":"2025-08-22 11:31","pubTimestamp":1755833491,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物涨超5%，高见177.9港元再创新高。截至发稿，涨5.42%，报177.1港元，成交额8.66亿港元。消息面上，8月21日，康方生物宣布，其自主研发的新型人源化抗IL-17A单克隆抗体古莫奇，在治疗活动性强直性脊柱炎的关键注册性III期临床研究中取得阳性结果，主要疗效终点ASAS20及亚组分析、关键次要终点ASAS40，及其他预先选定的多个次要终点均均获得成功，具有统计学显著性和临床意义的改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1333303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","LU1720050803.USD","IE00B543WZ88.USD","LU0348784397.USD","LU0417516571.SGD","BK4134","LU2488822045.USD","BK1574","IE00B5MMRT66.SGD","BK1161","LU0348783233.USD","LU1794554557.SGD","IE00BPRC5H50.USD","III"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.isg-one.com","stockEarnings":[{"period":"1week","weight":0.0278},{"period":"1month","weight":0.1995},{"period":"3month","weight":0.0953},{"period":"6month","weight":0.6518},{"period":"1year","weight":0.4899},{"period":"ytd","weight":0.5479}],"compareEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":0.0167},{"period":"3month","weight":0.0944},{"period":"6month","weight":0.0856},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Information Services Group, Inc.于2006年7月20日在特拉华州注册成立。该公司是一家全球领先的技术研究和咨询公司。ISG是超过900家客户、超过75家百强企业值得信赖的商业伙伴，致力于帮助企业、公共部门组织以及服务和技术提供商实现卓越运营和更快增长。该公司专门从事数字化转型服务，包括自动化、云和数据分析；采购咨询；托管治理和风险服务；网络载体服务；技术战略和运营设计；变革管理；市场情报和技术研究与分析。","yearOnYearQuotes":[{"month":1,"riseRate":0.470588,"avgChangeRate":0.025538},{"month":2,"riseRate":0.529412,"avgChangeRate":0.012941},{"month":3,"riseRate":0.333333,"avgChangeRate":0.043359},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.008159},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.028576},{"month":6,"riseRate":0.5,"avgChangeRate":0.015439},{"month":7,"riseRate":0.444444,"avgChangeRate":0.01427},{"month":8,"riseRate":0.555556,"avgChangeRate":0.010481},{"month":9,"riseRate":0.411765,"avgChangeRate":-0.011058},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.036309},{"month":11,"riseRate":0.647059,"avgChangeRate":0.057949},{"month":12,"riseRate":0.529412,"avgChangeRate":-0.000919}],"exchange":"NASDAQ","name":"信息服务","nameEN":"Information"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.9","shortVersion":"4.34.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信息服务,III,信息服务股票,信息服务股票老虎,信息服务股票老虎国际,信息服务行情,信息服务股票行情,信息服务股价,信息服务股市,信息服务股票价格,信息服务股票交易,信息服务股票购买,信息服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信息服务(III)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信息服务(III)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}